Onward Medical Management
Management criteria checks 1/4
Onward Medical's CEO is Dave Marver, appointed in Jul 2020, has a tenure of 4.83 years. total yearly compensation is €2.04M, comprised of 20.8% salary and 79.2% bonuses, including company stock and options. directly owns 2.14% of the company’s shares, worth €3.89M. The average tenure of the management team and the board of directors is 1.3 years and 4.1 years respectively.
Key information
Dave Marver
Chief executive officer
€2.0m
Total compensation
| CEO salary percentage | 20.83% |
| CEO tenure | 4.8yrs |
| CEO ownership | 2.1% |
| Management average tenure | 1.3yrs |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | €2m | €425k | -€36m |
| Sep 30 2024 | n/a | n/a | -€35m |
| Jun 30 2024 | n/a | n/a | -€35m |
| Mar 31 2024 | n/a | n/a | -€36m |
| Dec 31 2023 | €2m | €425k | -€36m |
| Sep 30 2023 | n/a | n/a | -€36m |
| Jun 30 2023 | n/a | n/a | -€36m |
| Mar 31 2023 | n/a | n/a | -€34m |
| Dec 31 2022 | €1m | €410k | -€33m |
| Sep 30 2022 | n/a | n/a | -€35m |
| Jun 30 2022 | n/a | n/a | -€38m |
| Mar 31 2022 | n/a | n/a | -€36m |
| Dec 31 2021 | €3m | €340k | -€34m |
| Sep 30 2021 | n/a | n/a | -€29m |
| Jun 30 2021 | n/a | n/a | -€24m |
| Mar 31 2021 | n/a | n/a | -€22m |
| Dec 31 2020 | €1m | €207k | -€20m |
Compensation vs Market: Dave's total compensation ($USD2.32M) is above average for companies of similar size in the German market ($USD814.49K).
Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.
CEO
Dave Marver (56 yo)
Mr. David L. Marver, also known as Dave, is Executive Council Member of CPC Equity Advisors, LP. He focuses on Medical. He is Member of Executive Council of Century Park Capital Partners, LLC.He focuses o...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 4.8yrs | €2.04m | 2.14% € 3.9m | |
| Chief Scientific Officer & Director | 11.2yrs | €661.18k | 1.76% € 3.2m | |
| Senior Finance Director | 1.3yrs | no data | no data | |
| Vice President of Operations | 1.8yrs | no data | no data | |
| Vice President of Legal | 1.3yrs | no data | no data | |
| Head of Strategy & Corporate Development | 1.3yrs | no data | no data | |
| Vice President of Sales | less than a year | no data | no data | |
| Director of People & Culture | 1.3yrs | no data | no data |
Experienced Management: 63E's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 5.3yrs | €2.04m | 2.14% € 3.9m | |
| Chief Scientific Officer & Director | 9.3yrs | €661.18k | 1.76% € 3.2m | |
| Non-Executive Director | 9.3yrs | no data | no data | |
| Non-Executive Chair | less than a year | €18.02k | no data | |
| Independent Non-Executive Director | less than a year | €16.07k | no data | |
| Independent Non-Executive Director | 2.7yrs | €92.91k | no data | |
| Independent Vice Chairperson | 6.3yrs | no data | 1.79% € 3.3m | |
| Independent Non-Executive Director | 2.9yrs | €51.00k | 0.050% € 90.4k |
Experienced Board: 63E's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/24 07:30 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Onward Medical N.V. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maria Vara Fernández | Bryan Garnier & Co |
| Dylan van Haaften | Bryan Garnier & Co |
| David Seynnaeve | Degroof Petercam |